Document:

EX-4.3

 Exhibit 4.3 

In accordance with Instruction 2 to Item 601 of Regulation S-K, below is a schedule setting forth details in which the
omitted executed warrants differ from the form of warrant that follows: 
  

			
	Holder	  	 
	Silicon Valley Bank	  	
	Life Sciences Loans, LLC	  	

 THIS WARRANT AND THE SHARES ISSUABLE HEREUNDER HAVE NOT BEEN REGISTERED UNDER THE SECURITIES ACT OF 1933, AS AMENDED (THE
“ACT”), OR THE SECURITIES LAWS OF ANY STATE AND, EXCEPT AS SET FORTH IN SECTIONS 5.3 AND 5.4 BELOW, MAY NOT BE OFFERED, SOLD, PLEDGED OR OTHERWISE TRANSFERRED UNLESS AND UNTIL REGISTERED UNDER SAID ACT AND LAWS
OR, IN THE OPINION OF LEGAL COUNSEL, TN FORM AND SUBSTANCE SATISFACTORY TO THE COMPANY, SUCH OFFER, SALE, PLEDGE OR OTHER TRANSFER IS EXEMPT FROM SUCH REGISTRATION. 

WARRANT TO PURCHASE COMMON STOCK 

Company: ACUTUS MEDICAL, INC. 
 Number of Shares of
Common Stock: [37,037] 
 Warrant Price: $0.54 per share 

Issue Date: January 30, 2015 
 Expiration Date:
January 30, 2025        See also Section 5.1(b). 

	Credit Facility:	 This Warrant to Purchase Common Stock (“Warrant”) is issued in connection with that
certain Loan and Security Agreement of even date herewith between Silicon Valley Bank and the Company (the “Loan Agreement”). 

THIS WARRANT CERTIFIES THAT, for good and valuable consideration, [Silicon Valley Bank / LIFE SCIENCES LOANS, LLC] (together with any
successor or permitted assignee or transferee of this Warrant or of any shares issued upon exercise hereof, “Holder”) is entitled to purchase the number of fully paid and non-assessable shares of the
above-stated common stock (the “Common Stock”) of the above-named company (the “Company”) at the above-stated Warrant Price, all as set forth above and as adjusted pursuant
to Section 2 of this Warrant, subject to the provisions and upon the terms and conditions set forth in this Warrant. The number of fully paid and non-assessable shares (the
“Shares”) for which this Warrant shall be exercisable shall equal the quotient derived by dividing (a) 2.00% of the aggregate Growth Capital Advances made under the Loan Agreement divided by (b) the Warrant
Price, all as set forth above and as adjusted pursuant to Section 2 of this Warrant. 
 SECTION
1.    EXERCISE. 
 1.1    Method of Exercise. Holder may at any time and from time to
time exercise this Warrant, in whole or in part, by delivering to the Company the original of this Warrant together with a duly executed Notice of Exercise in substantially the form attached hereto as Appendix 1 and, unless Holder is exercising this
Warrant pursuant to a cashless exercise set forth in Section 1.2, a check, wire transfer of same-day funds (to an account designated by the Company), or other form of payment acceptable to the Company for
the aggregate Warrant Price for the Shares being purchased. 

  
 1 

 1.2    Cashless Exercise. On any exercise of this Warrant, in
lieu of payment of the aggregate Warrant Price in the manner as specified in Section 1.1 above, but otherwise in accordance with the requirements of Section 1.1, Holder may elect to receive Shares equal to the value of this Warrant, or
portion hereof as to which this Warrant is being exercised. Thereupon, the Company shall issue to the Holder such number of fully paid and non-assessable Shares as are computed using the following formula:

  

					
	X	  	=	  	Y(A – B)/A

 where: 
  

					
	X	  	=	  	the number of Shares to be issued to the Holder;
			
	Y	  	=	  	the number of Shares with respect to which this Warrant is being exercised (inclusive of the Shares surrendered to the Company in payment of the aggregate Warrant Price);
			
	A	  	=	  	the Fair Market Value (as determined pursuant to Section 1.3 below) of one Share; and
			
	B	  	=	  	the Warrant Price.

 1.3    Fair Market Value. If the Company’ s Common Stock is then traded
or quoted on a nationally recognized securities exchange, inter-dealer quotation system or over-the-counter market (a “Trading
Market”), the fair market value of a Share shall be the closing price or last sale price of a share of Common Stock reported for the Business Day immediately before the date on which Holder delivers this Warrant together
with its Notice of Exercise to the Company (or in the instance where the Warrant is exercised immediately prior to the effectiveness of the Company’s initial public offering, the “price to public” per share price specified in the
final prospectus relating to such offering prior to any underwriting discounts or commissions). If the Company’s Common Stock is not traded in a Trading Market, the Board of Directors of the Company shall determine the fair market value of a
Share in its reasonable good faith judgment. 
 1.4    Delivery of Certificate and New Warrant. Within a
reasonable time after Holder exercises this Warrant in the manner set forth in Section 1.1 or 1.2 above, the Company shall deliver to Holder a certificate representing the Shares issued to Holder upon such exercise and, if this Warrant has not
been fully exercised and has not expired, a new warrant of like tenor representing the Shares not so acquired. 

1.5    Replacement of Warrant. On receipt of evidence reasonably satisfactory to the Company of the loss, theft,
destruction or mutilation of this Warrant and, in the case of loss, theft or destruction, on delivery of an indemnity agreement reasonably satisfactory in form, substance and amount to the Company or, in the case of mutilation, on surrender of this
Warrant to the Company for cancellation, the Company shall, within a reasonable time, execute and deliver to Holder, in lieu of this Warrant, a new warrant of like tenor and amount. 

1.6    Treatment of Warrant Upon Acquisition of Company. 

(a)    Acquisition. For the purpose of this Warrant, “Acquisition” means any transaction or
series of related transactions involving: (1) the closing of the sale, transfer or other disposition of all or substantially all the assets of the Company and its subsidiaries taken as a whole, except where such sale, transfer, or other
disposition is to a wholly-owned subsidiary of this corporation, 

  
 2 

 
(2) the consummation of the merger or consolidation of (i) the Company with or into another entity or (ii) any subsidiary of the Company with or into another entity wherein the Company
issues shares of its capital stock in connection therewith, except, in the case of either of clause (i) or (ii), a merger or consolidation in which the holders of capital stock of the Company immediately prior to such merger or consolidation
continue to hold at least a majority of the voting power of the capital stock of the Company or the surviving or acquiring entity, (3) the closing of the transfer (whether by merger, consolidation or otherwise), in one transaction or a series
of related transactions, to a person or group of affiliated persons (other than an underwriter of the Company’s securities), of the Company’s securities if, after such closing, such person or group of affiliated persons would hold a
majority of the outstanding voting stock of this corporation (or the surviving or acquiring entity), (4) a liquidation, dissolution or winding up of the Company, (5) the grant of an irrevocable, exclusive, worldwide license to all or
substantially all of the assets or intellectual property of the Company and its subsidiaries taken as a whole to a third party, or (6) (i) the Company’s filing of or the filing against it of a petition in bankruptcy or a petition to take
advantage of any insolvency act, (ii) the adjudication of the Company as bankrupt, (iii) the Company’s filing of a petition or answer seeking reorganization or arrangement under any bankruptcy laws or any other similar law or statute
of the United States of America or any other juris diction or (iv) the Company’s consent to an appointment of a receiver for itself or for the whole or any substantial part of its property; provided, however, that a transaction shall not
constitute an Acquisition if its sole purpose is to change the state of the Company’s incorporation or to create a holding company that will be owned in substantially the same proportions by the persons who held this corporation’s
securities immediately prior to such transaction. Notwithstanding the prior sentence, the sale of capital stock for capital raising purposes shall not be deemed an “Acquisition”. 

(b)    Treatment of Warrant at Acquisition. In the event of an Acquisition in which the consideration to be
received by the Company’s stockholders consists solely of cash, solely of Marketable Securities or a combination of cash and Marketable Securities (a “Cash/Public Acquisition”), and the fair market value of one Share as
determined in accordance with Section 1.3 above would be greater than the Warrant Price in effect on such date immediately prior to such Cash/Public Acquisition, and Holder has not exercised this Warrant pursuant to Section 1.1 above as to
all Shares, then this Warrant shall automatically be converted into the right to receive the consideration payable in such Cash/Public Acquisition with respect to the Shares, net of the aggregate Warrant Price. In connection with the treatment of
the Warrant pursuant to this Section 1.6(b), Holder shall be deemed to have restated each of the representations and warranties in Section 4 of the Warrant as the date thereof and the Company shall promptly notify the Holder of the number
of Shares (or such other securities) issued upon exercise. In the event of a Cash/Public Acquisition where the fair market value of one Share as determined in accordance with Section 1.3 above would be less than the Warrant Price in effect
immediately prior to such Cash/Public Acquisition, then this Warrant will expire immediately prior to the consummation of such Cash/Public Acquisition. 

(c)    Upon the closing of any Acquisition other than a Cash/Public Acquisition defined above, the acquiring, surviving or
successor entity shall assume the obligations of this Warrant, and this Warrant shall thereafter be exercisable for the same securities and/or other property as would have been paid for the Shares issuable upon exercise of the unexercised portion of
this Warrant as if such Shares were outstanding on and as of the closing of such Acquisition, subject to further adjustment from time to time in accordance with the provisions of this Warrant. 

(d)    As used in this Warrant, “Marketable Securities” means securities meeting all of the
following requirements: (i) the issuer thereof is then subject to the reporting requirements of Section 13 or Section 15(d) of the Securities Exchange Act of 1934, as amended (the “Exchange Act”), and is then
current in its filing of all required reports and other information under the Act and the Exchange Act; (ii) the class and series of shares or other security of the issuer that would be received by

  
 3 

 
Holder in connection with the Acquisition were Holder to exercise this Warrant on or prior to the closing thereof is then traded in Trading Market, and (iii) following the closing of such
Acquisition, Holder would not be restricted from publicly re-selling all of the issuer’s shares and/or other securities that would be received by Holder in such Acquisition were Holder to exercise or
convert this Warrant in full on or prior to the closing of such Acquisition, except to the extent that any such restriction (x) arises solely under federal or state securities laws, rules or regulations, and (y) does not extend beyond six
(6) months from the closing of such Acquisition. 
 SECTION 2.    ADJUSTMENTS TO THE SHARES AND WARRANT
PRICE. 
 2.1    Stock Dividends, Splits, Etc. If the Company declares or pays a dividend or distribution on
the outstanding shares of the Common Stock payable in securities or property (other than cash), then upon exercise of this Warrant, for each Share acquired, Holder shall receive, without additional cost to Holder, the total number and kind of
securities and property which Holder would have received had Holder owned the Shares of record as of the date the dividend or distribution occurred. If the Company subdivides the outstanding shares of the Common Stock by reclassification or
otherwise into a greater number of shares, the number of Shares purchasable hereunder shall be proportionately increased and the Warrant Price shall be proportionately decreased. If the outstanding shares of the Common Stock are combined or
consolidated, by reclassification or otherwise, into a lesser number of shares, the Warrant Price shall be proportionately increased and the number of Shares shall be proportionately decreased. 

2.2    Reclassification, Exchange, Combinations or Substitution. Upon any event whereby all of the outstanding
shares of the Common Stock are reclassified, exchanged, combined, substituted, or replaced for, into, with or by Company securities of a different class and/or series, then from and after the consummation of such event, this Warrant will be
exercisable for the number, class and series of Company securities that Holder would have received had the Shares been outstanding on and as of the consummation of such event, and subject to further adjustment thereafter from time to time in
accordance with the provisions of this Warrant. The provisions of this Section 2.2 shall similarly apply to successive reclassifications, exchanges, combinations substitutions, replacements or other similar events. 

2.3    Intentionally Omitted. 

2.4    Intentionally Omitted. 

2.5    No Fractional Share. No fractional Share shall be issuable upon exercise of this Warrant and the number of
Shares to be issued shall be rounded down to the nearest whole Share. If a fractional Share interest arises upon any exercise of the Warrant, the Company shall eliminate such fractional Share interest by paying Holder in cash the amount computed by
multiplying the fractional interest by (i) the fair market value (as determined in accordance with Section 1.3 above) of a full Share, less (ii) the then-effective Warrant Price. 

2.6    Notice /Certificate as to Adjustments. Upon each adjustment of the Warrant Price, Common Stock and/or number
of Shares, the Company, at the Company’s expense, shall notify Holder in writing within a reasonable time setting forth the adjustments to the Warrant Price, class and/or number of Shares and facts upon which such adjustment is based. The
Company shall, upon written request from Holder, furnish Holder with a certificate of its Chief Financial Officer, including computations of such adjustment and the Warrant Price, class and number of Shares in effect upon the date of such
adjustment. 
 SECTION 3.    REPRESENTATIONS AND COVENANTS OF THE COMPANY. 

  
 4 

 3.1    Representations and Warranties. The Company represents and
warrants to, and agrees with, the Holder as follows: 
 (a)    The initial Warrant Price referenced on the first page of
this Warrant is not greater than the price per share at which shares of Company Common Stock or options to purchase shares of Company Common Stock were last sold and issued prior to the Issue Date hereof. 

(b)    All Shares which may be issued upon the exercise of this Warrant, shall, upon issuance, be duly authorized, validly
issued, fully paid and non-assessable, and free of any liens and encumbrances except for restrictions on transfer provided for herein or under applicable federal and state securities laws. The Company
covenants that it shall at all times cause to be reserved and kept available out of its authorized and unissued capital stock such number of securities as will be sufficient to permit the exercise in full of this Warrant. 

(c)    The Company’s capitalization table attached hereto as Schedule 1 is true and complete, in all material
respects, as of the Issue Date. 
 3.2    Notice of Certain Events. If the Company proposes at any time to: 

(a)    declare any dividend or distribution upon the outstanding shares of the Company’s stock, whether in cash,
property, stock, or other securities and whether or not a regular cash dividend; 
 (b)    offer for subscription or
sale pro rata to the holders of the outstanding shares any additional shares of any class or series of the Company’s stock (other than pursuant to contractual pre-emptive rights); 

(c)    effect any reclassification, exchange, combination, substitution, reorganization or recapitalization of the
outstanding shares of the Common Stock; 
 (d)    effect an Acquisition or to liquidate, dissolve or wind up; or 

(e)    effect an initial, underwritten offering and sale of its securities to the public pursuant to an effective
registration statement under the Act (the “IPO”); 
 then, in connection with each such event, the Company shall give Holder: 

(1) in the case of the matters referred to in (a) and (b) above, at least seven (7) Business Days prior written
notice of the earlier to occur of the effective date thereof or the date on which a record will be taken for such dividend, distribution, or subscription rights (and specifying the date on which the holders of outstanding shares of the Common Stock
will be entitled thereto) or for determining rights to vote, if any, 
 (2) in the case of the matters referred to in
(c) and (d) above at least seven (7) Business Days prior written notice of the date when the same will take place (and specifying the date on which the holders of outstanding shares of the Class will be entitled to exchange their
shares for the securities or other property deliverable upon the occurrence of such event and such reasonable information as Holder may reasonably require regarding the treatment of this Warrant in connection with such event giving rise to the
notice); and 

  
 5 

 (3) with respect to the IPO, at least seven (7) Business Days prior
written notice of the date on which the Company proposes to file its registration statement in connection therewith. 
 Company will also provide
information requested by Holder that is reasonably necessary to enable Holder to comply with Holder’s accounting or reporting requirements. 

SECTION 4.    REPRESENTATIONS, WARRANTIES OF THE HOLDER. 

The Holder represents and warrants to the Company as follows: 

4.1    Purchase for Own Account. This Warrant and the Shares to be acquired upon exercise of this Warrant by Holder
are being acquired for investment for Holder’s account, not as a nominee or agent, and not with a view to the public resale or distribution within the meaning of the Act. Holder also represents that it has not been formed for the specific
purpose of acquiring this Warrant or the Shares. 
 4.2    Disclosure of Information. Holder is aware of the
Company’s business affairs and financial condition and has received or has had full access to all the information it considers necessary or appropriate to make an informed investment decision with respect to the acquisition of this Warrant and
its underlying securities. Holder further has had an opportunity to ask questions and receive answers from the Company regarding the terms and conditions of the offering of this Warrant and its underlying securities and to obtain additional
information (to the extent the Company possessed such information or could acquire it without unreasonable effort or expense) necessary to verify any information furnished to Holder or to which Holder has access. 

4.3    Investment Experience. Holder understands that the purchase of this Warrant and its underlying securities
involves substantial risk. Holder has experience as an investor in securities of companies in the development stage and acknowledges that Holder can bear the economic risk of such Holder’s investment in this Warrant and its underlying
securities and has such knowledge and experience in financial or business matters that Holder is capable of evaluating the merits and risks of its investment in this Warrant and its underlying securities and/or has a preexisting personal or business
relationship with the Company and certain of its officers, directors or controlling persons of a nature and duration that enables Holder to be aware of the character, business acumen and financial circumstances of such persons. 

4.4    Accredited Investor Status. Holder is an “accredited investor” within the meaning of Regulation D
promulgated under the Act. 
 4.5    The Act. Holder understands that this Warrant and the Shares issuable upon
exercise hereof have not been registered under the Act in reliance upon a specific exemption therefrom, which exemption depends upon, among other things, the bona fide nature of the Holder’s investment intent as expressed herein. Holder
understands that this Warrant and the Shares issued upon any exercise hereof must be held indefinitely unless subsequently registered under the Act and qualified under applicable state securities laws, or unless exemption from such registration and
qualification are otherwise available. Holder is aware of the provisions of Rule 144 promulgated under the Act. 

4.6    Market Stand-off Agreement. The Holder agrees that the Shares shall
be subject to the Market Standoff provisions in Section 1.13 of the Amended and Restated Investor Rights Agreement dated as of June 7, 2013, by and among the Company and the persons and entities set forth therein. 

  
 6 

 4.7    No Voting Rights. Holder, as a Holder of this Warrant,
will not have any voting rights until the exercise of this Warrant. 
 SECTION 5.    MISCELLANEOUS. 

5.1    Term and Automatic Conversion Upon Expiration. 

(a)    Term. Subject to the provisions of Section 1.6 above, this Warrant is exercisable in whole or in part at
any time and from time to time on or before 6:00 PM, Pacific time, on the Expiration Date and shall be void thereafter. 

(b)    Automatic Cashless Exercise upon Expiration. In the event that, upon the Expiration Date, the fair market
value of one Share (or other security issuable upon the exercise hereof) as determined in accordance with Section 1.3 above is greater than the Warrant Price in effect on such date, then this Warrant shall automatically be deemed on and as of
such date to be exercised pursuant to Section 1.2 above as to all Shares (or such other securities) for which it shall not previously have been exercised, and the Company shall, within a reasonable time, deliver a certificate representing the
Shares (or such other securities) issued upon such exercise to Holder. 
 5.2    Legends. The Shares (and the
securities issuable, directly or indirectly, upon conversion of the Shares, if any) shall be imprinted with a legend in substantially the following form: 

THE SHARES EVIDENCED BY THIS CERTIFICATE HAVE NOT BEEN REGISTERED UNDER THE SECURITIES ACT OF 1933, AS AMENDED (THE
“ACT”), OR THE SECURITIES LAWS OF ANY STATE AND, EXCEPT AS SET FORTH IN THAT CERTAIN WARRANT TO PURCHASE COMMON STOCK ISSUED BY THE ISSUER TO [SILICON VALLEY BANK / LIFE SCIENCES LOANS, LLC] DATED JANUARY 30, 2015, MAY
NOT BE OFFERED, SOLD, PLEDGED OR OTHERWISE TRANSFERRED UNLESS AND UNTIL REGISTERED UNDER SAID ACT AND LAWS OR, IN THE OPINION OF LEGAL COUNSEL, IN FORM AND SUBSTANCE SATISFACTORY TO THE ISSUER, SUCH OFFER, SALE, PLEDGE OR OTHER TRANSFER IS EXEMPT
FROM SUCH REGISTRATION. 
 5.3    Compliance with Securities Laws on Transfer. This Warrant and the Shares
issuable upon exercise of this Warrant (and the securities issuable, directly or indirectly, upon conversion of the Shares, if any) may not be transferred or assigned in whole or in part except in compliance with applicable federal and state
securities laws by the transferor and the transferee (including, without limitation, the delivery of investment representation letters and legal opinions reasonably satisfactory to the Company, as reasonably requested by the Company). Additionally,
the Company shall also not require an opinion of counsel if there is no material question as to the availability of Rule 144 promulgated under the Act. 

5.4    Transfer Procedure. Subject to the provisions of Section 5.3 and upon providing the Company with
written notice, [Silicon Valley Bank / LIFE SCIENCES LOANS, LLC] and any subsequent Holder may transfer all or part of this Warrant or the Shares issuable upon exercise of this Warrant (or the securities issuable directly or indirectly, upon
conversion of the Shares, if any) to any transferee, provided, however, in connection with any such transfer,[Silicon Valley Bank / LIFE SCIENCES LOANS, LLC] or any subsequent Holder will give the Company notice of the portion of the Warrant being
transferred with the name, address and taxpayer identification number of the transferee and 

  
 7 

 
Holder will surrender this Warrant to the Company for reissuance to the transferee(s) (and Holder if applicable); and provided further, that any subsequent transferee other than SVB Financial
Group shall agree in writing with the Company to be bound by all of the terms and conditions of this Warrant. Notwithstanding any contrary provision herein, at all times prior to the IPO, Holder may not, without the Company’s prior written
consent, transfer this Warrant or any portion hereof, or any Shares issued upon any exercise hereof, or any shares or other securities issued upon any conversion of any Shares issued upon any exercise hereof, to any person or entity who directly
competes with the Company, except in connection with an Acquisition of the Company by such a direct competitor. 

5.5    Notices. All notices and other communications hereunder from the Company to the Holder, or vice versa, shall
be deemed delivered and effective (i) when given personally, (ii) on the third (3rd) Business Day after being mailed by first-class registered or certified mail, postage prepaid, (iii)upon actual receipt if given by facsimile or electronic
mail and such receipt is confirmed in writing by the recipient, or (iv) on the first Business Day following delivery to a reliable overnight courier service, courier fee prepaid, in any case at such address as may have been furnished to the
Company or Holder, as the case may be, in writing by the Company or such Holder from time to time in accordance with the provisions of this Section 5.5. All notices to Holder shall be addressed as follows until the Company receives notice of a
change of address in connection with a transfer or otherwise: 

[                       
             ] 
 Attn: [
                                        ] 

Telephone: ([        ])
[        -            ] 
 Email
address:
[                    @            .        ] 

Notice to the Company shall be addressed as follows until Holder receives notice of a change in address: 

ACUTUS MEDICAL, INC. 
 Attn:
[                                        ] 

10840 Thornmint Road, Suite 100 

San Diego, CA 92127 
 Telephone:
([            ]) [        -            ] 

Facsimile: ([            ])
[            -        ] 
 Email:
[                    @        .        ] 

With a copy (which shall not constitute notice) to: 

Wilson Sonsini Goodrich & Rosati 

Attn:
[                                        ] 

650 Page Mill Road 
 Palo Alto,
CA 94304 
 Telephone: ([            ])
[        -            ] 
 Facsimile:
([            ])             -        ] 

Email:
[                    @            .        ] 

5.6    Waiver. This Warrant and any term hereof may be changed, waived, discharge d or terminated (either generally
or in a particular instance and either retroactively or prospectively) only by 

  
 8 

 
an instrument in writing signed by the party against which enforcement of such change, waiver, discharge or termination is sought. 

5.7    Attorney’s Fees. In the event of any dispute between the parties concerning the terms and provisions of
this Warrant, the party prevailing in such dispute shall be entitled to collect from the other party all costs incurred in such dispute, including reasonable attorneys’ fees. 

5.8    Counterparts; Facsimile /Electronic Signatures. This Warrant may be executed in counterparts, all of which
together shall constitute one and the same agreement. Any signature page delivered electronically or by facsimile shall be binding to the same extent as an original signature page with regards to any agreement subject to the terms hereof or any
amendment thereto. 
 5.9    Governing Law. This Warrant shall be governed by and construed in accordance with
the laws of the State of California, without giving effect to its principles regarding conflicts of law. 

5.10    Headings. The headings in this Warrant are for purposes of reference only and shall not limit or otherwise
affect the meaning of any provision of this Warrant. 
 5.11    Business Days. “Business
Day” is any day that is not a Saturday, Sunday or a day on which Silicon Valley Bank is closed. 
 [Remainder of page left blank
intentionally] 
 [Signature page follows] 

  
 9 

 IN WITNESS WHEREOF, the parties have causes this Warrant to Purchase Common Stock to be
executed by their duly authorized representatices effective as of the Issue Date written above. 
  

			
	“COMPANY”
	
	ACUTUS MEDICAL, INC.
		
	By:	 	
                     

	Name:	 	  

	Title:	 	
	
	“HOLDER”
	
	[Silicon Valley Bank / LIFE SCIENCE LOANS, LLC]
	
	By:
		
	By:	 	
                     

	Name:	 	
	Title:	 	

 APPENDIX 1 

 SCHEDULE IEX-4.4

 Exhibit 4.4 

In accordance with Instruction 2 to Item 601 of Regulation S-K, below is a schedule setting forth details in which the
omitted executed warrants differ from the form of warrant that follows: 
  

					
	 Holders
	  	Number of Shares	 
	 OrbiMed Private Investments IV, LP
	  	 	586,741	 
	 Revelation Alpine, LLC
	  	 	263,725	 
	 Philips Holding USA Inc.
	  	 	1,210,290	 
	 Deerfield Private Design Fund III, L.P.
	  	 	1,574,183	 
	 AMXeraya, Ltd
	  	 	1,246,004	 

 THIS WARRANT AND THE UNDERLYING SECURITIES HAVE NOT BEEN REGISTERED UNDER THE SECURITIES ACT OF 1933, AS AMENDED (THE
“ACT”), OR UNDER THE SECURITIES LAWS OF ANY STATE. THESE SECURITIES MAY NOT BE OFFERED, SOLD OR OTHERWISE TRANSFERRED, PLEDGED OR HYPOTHECATED EXCEPT AS PERMITTED UNDER THE ACT AND APPLICABLE STATE SECURITIES LAWS IN
ACCORDANCE WITH APPLICABLE REGISTRATION REQUIREMENTS OR AN EXEMPTION THEREFROM. THE ISSUER OF THESE SECURITIES MAY REQUIRE AN OPINION OF COUNSEL REASONABLY SATISFACTORY TO THE ISSUER THAT SUCH OFFER, SALE, TRANSFER, PLEDGE OR HYPOTHECATION OTHERWISE
COMPLIES WITH THE ACT AND ANY APPLICABLE STATE SECURITIES LAWS. THIS WARRANT MUST BE SURRENDERED TO THE COMPANY OR ITS TRANSFER AGENT AS A CONDITION PRECEDENT TO THE SALE, TRANSFER, PLEDGE OR HYPOTHECATION OF ANY INTEREST IN ANY OF THE SECURITIES
REPRESENTED HEREBY. 
 WARRANT TO PURCHASE SHARES OF 

COMMON STOCK 
 of 

ACUTUS MEDICAL, INC. 

Dated as of June 7, 2018 

Void after the date specified in Section 7 
  

			
	 Warrant Coverage Amount: $[        ]
	  	 Warrant to Purchase Shares of

Common Stock (subject to adjustment)

 THIS CERTIFIES THAT, for value received, [the
“Holder”], is entitled, subject to the provisions and upon the terms and conditions set forth herein, to purchase from Acutus Medical, Inc., a Delaware corporation (the
“Company” ), shares of the Company’s Common Stock, $0.001 par value per share (the “Shares” ), in the amounts,
at such times and at the price per share set forth in Section 1. The term “Warrant” as used herein shall include this Warrant and any warrants delivered in substitution or
exchange therefor as provided herein , and is issued in connection with the issuance of convertible promissory notes (the “Notes”) pursuant to the Note and Warrant Purchase Agreement
dated June 7, 2018 (the “Purchase Agreement”). The holder of this Warrant is subject to certain restrictions set forth herein. 

The following is a statement of the rights of the Holder and the conditions to which this Warrant is subject, and to which Holder, by
acceptance of this Warrant, agrees: 
 1.    Number and Price of Shares; Exercise Period. 

(a)    Number of Shares. Subject to any previous exercise of the Warrant, the Holder shall have the right to
purchase up to that number of Shares equal to (x) seventy-five percent (75%) of the Holder’s 

 
Warrant Coverage Amount (as defined in the Purchase Agreement and which is set forth above), divided by (y) the lower of (i) the lowest per share purchase price paid by cash purchasers
of the securities issued in the Next Equity Financing (as defined in the Notes) or (ii) $1.714, as may be adjusted pursuant hereto, prior to (or in connection with) the expiration of this Warrant as provided in Section 7. 

(b)    Exercise Price. The exercise price per Share shall be equal to $0.01, subject to adjustment pursuant
hereto (the “Exercise Price”). 

(c)    Exercise Period. This Warrant shall be exercisable, in whole or in part, from and after the date
hereof and prior to (or in connection with) the expiration of this Warrant as set forth in Section 7 (the “Expiration Date”); provided that, if the fair market value of a share
of Common Stock (as determined in accordance with Section 2(b) below) exceeds the Exercise Price on the Expiration Date, then this Warrant shall be deemed to have been exercised in full (to the extent not previously exercised) on a
“cashless exercise” basis in accordance with Section 2(b) below at 5:00 P.M. Pacific time on the Expiration Date. 

2.    Exercise of the Warrant. 

(a)    Exercise. The purchase rights represented by this Warrant may be exercised at the election of the
Holder, in whole or in part, in accordance with Section 1, by: 
 (i)    the tender to the Company at its
principal office (or such other office or agency as the Company may designate) of a notice of exercise in the form of Exhibit A (the “Notice of Exercise”), duly completed and executed
by or on behalf of the Holder, together with the surrender of this Warrant; and 
 (ii)    the payment to the Company
of an amount equal to (x) the Exercise Price multiplied by (y) the number of Shares being purchased, by (a) wire transfer or certified cashier’s or other check acceptable to the Company and payable to the order of the Company;
(b) surrender and cancellation of promissory notes or other instruments representing indebtedness of the Company to the Holder; or (c) a combination of (a) and (b). 

(b)    Net Issue Exercise. In lieu of exercising this Warrant pursuant to Section 2(a)(ii), if the fair
market value of one Share is greater than the Exercise Price (at the date of calculation as set forth below), the Holder may elect to receive a number of Shares equal to the value of this Warrant (or of any portion of this Warrant being canceled) by
surrender of this Warrant at the principal office of the Company (or such other office or agency as the Company may designate) together with a properly completed and executed Notice of Exercise reflecting such election, in which event the Company
shall issue to the Holder that number of Shares computed using the following formula: 
  

							
		 	X	 	=	 	     Y (A 1/N B)    

A

 Where: 
  

					
	 X
	  	=	    	The number of Shares to be issued to the Holder
			
	 Y
	  	=	    	The number of Shares purchasable under this Warrant or, if only a portion of the Warrant is being exercised, the portion of the Warrant being canceled (at the date of such calculation)
			
	 A
	  	=	    	The fair market value of one Share (at the date of such calculation)
			
	 B
	  	=	    	The Exercise Price (as adjusted to the date of such calculation)

 For purposes of the calculation above, the fair market value of one Share shall be determined by the Board of
Directors of the Company, acting in good faith; provided, however, that: 

  
 - 2 - 

 (i)    where a public market exists for the Company’s common stock
at the time of such exercise, the fair market value per Share shall be the average of the closing bid prices of the common stock or the closing price quoted on the national securities exchange on which the common stock is listed as published in the
Wall Street Journal, as applicable, for the ten (10) trading day period ending five (5) trading days prior to the date of determination of fair market value; and 

(ii)    if the Warrant is exercised in connection with the Company’s initial public offering of common stock, the
fair market value per Share shall be the per share offering price to the public of the Company’s initial public offering. 

(c)    Stock Certificates. The rights under this Warrant shall be deemed to have been exercised and the
Shares issuable upon such exercise shall be deemed to have been issued immediately prior to the close of business on the date this Warrant is exercised in accordance with its terms, and the person entitled to receive the Shares issuable upon such
exercise shall be treated for all purposes as the holder of record of such Shares as of the close of business on such date. As promptly as reasonably practicable on or after such date, the Company shall issue and deliver to the person or persons
entitled to receive the same a certificate or certificates for that number of shares issuable upon such exercise. In the event that the rights under this Warrant are exercised in part and have not expired, the Company shall execute and deliver a new
Warrant reflecting the number of Shares that remain subject to this Warrant. 
 (d)    No Fractional Shares or
Scrip. No fractional shares or scrip representing fractional shares shall be issued upon the exercise of the rights under this Warrant. In lieu of such fractional share to which the Holder would otherwise be entitled, the Company shall make
a cash payment equal to the Exercise Price multiplied by such fraction. 
 (e)    Conditional Exercise.
The Holder may exercise this Warrant conditioned upon (and effective immediately prior to) consummation of any transaction that would cause the expiration of this Warrant pursuant to Section 7 by so indicating in the notice of exercise.

 (f)    Reservation of Stock. The Company agrees during the term the rights under this Warrant are
exercisable to take all reasonable action to reserve and keep available from its authorized and unissued shares of common stock for the purpose of effecting the exercise of this Warrant such number of shares as shall from time to time be sufficient
to effect the exercise of the rights under this Warrant; and if at any time the number of authorized but unissued shares of common stock shall not be sufficient for purposes of the exercise of this Warrant in accordance with its terms, without
limitation of such other remedies as may be available to the Holder, the Company will use all reasonable efforts to take such corporate action as may, in the opinion of counsel, be necessary to increase its authorized and unissued shares of its
common stock to a number of shares as shall be sufficient for such purposes. 
 3.    Replacement of the Warrant.
Subject to the receipt of evidence reasonably satisfactory to the Company of the loss, theft, destruction or mutilation of this Warrant and, in the case of loss, theft or destruction, on delivery of an indemnity agreement reasonably satisfactory
in form and substance to the Company or, in the case of mutilation, on surrender and cancellation of this Warrant, the Company at the expense of the Holder shall execute and deliver, in lieu of this Warrant, a new warrant of like tenor and amount.

 4.    Transfer of the Warrant. 

(a)    Warrant Register. The Company shall maintain a register (the “Warrant
Register”) containing the name and address of the Holder or Holders. Until this Warrant is transferred on the Warrant Register in accordance herewith, the Company may treat the Holder as shown on the Warrant Register as
the absolute owner of this Warrant for all purposes, notwithstanding any notice to the contrary. Any Holder of this Warrant (or of any portion of this Warrant) may change its address as shown on the Warrant Register by written notice to the Company
requesting a change. 

  
 - 3 - 

 (b)    Warrant Agent. The Company may appoint an agent for
the purpose of maintaining the Warrant Register referred to in Section 4(a), issuing the Shares or other securities then issuable upon the exercise of the rights under this Warrant; exchanging this Warrant; replacing this Warrant or conducting
related activities. 
 (c)    Transferability of the Warrant. Subject to the provisions of
this Warrant with respect to compliance with the Securities Act of 1933, as amended (the “Securities Act”) and limitations on assignments and transfers, including without limitation
compliance with the restrictions on transfer set forth in Section 5, title to this Warrant may be transferred by endorsement (by the transferor and the transferee executing the assignment form attached as Exhibit B (the
“Assignment Form”) and delivery in the same manner as a negotiable instrument transferable by endorsement and delivery. 

(d)    Exchange of the Warrant upon a Transfer. On surrender of this Warrant (and a properly endorsed
Assignment Form) for exchange, subject to the provisions of this Warrant with respect to compliance with the Securities Act and limitations on assignments and transfers, the Company shall issue to or on the order of the Holder a new warrant or
warrants of like tenor, in the name of the Holder or as the Holder (on payment by the Holder of any applicable transfer taxes) may direct, for the number of shares issuable upon exercise hereof, and the Company shall register any such transfer upon
the Warrant Register. This Warrant (and the securities issuable upon exercise of the rights under this Warrant) must be surrendered to the Company or its warrant or transfer agent, as applicable, as a condition precedent to the sale, pledge,
hypothecation or other transfer of any interest in any of the securities represented hereby. 
 (e)    Minimum
Transfer. This Warrant may not be transferred in part unless such transfer is to a transferee who, pursuant to such transfer, receives the right to purchase at least 50,000 Shares hereunder (as adjusted from time to time in accordance with
Section 5(h)). 
 (f)    Taxes. In no event shall the Company be required to pay any tax which may be
payable in respect of any transfer involved in the issue and delivery of any certificate in a name other than that of the Holder, and the Company shall not be required to issue or deliver any such certificate unless and until the person or persons
requesting the issue thereof shall have paid to the Company the amount of such tax or shall have established to the satisfaction of the Company that such tax has been paid or is not payable. 

5.    Restrictions on Transfer of the Warrant and Shares; Compliance with Securities Laws. 

By acceptance of this Warrant, the Holder agrees to comply with the following: 

(a)    Restrictions on Transfers. Subject to Section 5(b), this Warrant may not be transferred or
assigned in whole or in part without the Company’s prior written consent (which shall not be unreasonably withheld), and any attempt by Holder to transfer or assign any rights, duties or obligations that arise under this Warrant without such
permission shall be void. Any transfer of this Warrant or the Shares (the “Securities”) must be in compliance with all applicable federal and state securities laws. The Holder agrees
not to make any sale, assignment, transfer, pledge or other disposition of all or any portion of the Securities, or any beneficial interest therein, unless and until the transferee thereof has agreed in writing for the benefit of the Company to take
and hold such Securities subject to, and to be bound by, the terms and conditions set forth in this Warrant to the same extent as if the transferee were the original Holder hereunder, and 

(i)    there is then in effect a registration statement under the Securities Act covering such proposed disposition and
such disposition is made in accordance with such registration statement, or 
 (ii)    (A) such Holder shall have given
prior written notice to the Company of such Holder’s intention to make such disposition and shall have furnished the Company with a detailed description of the manner and circumstances of the proposed disposition, (B) the transferee shall
have confirmed to the satisfaction of the Company in writing, substantially in the form of Exhibit A-1, that the Securities are being acquired (i) solely for the transferee’s own account and not as a
nominee for any other party, (ii) for investment and (iii) not with a view toward distribution or resale, and shall have confirmed such other matters related thereto as may be reasonably requested by the Company, and (C) to the extent
requested by the Company, such Holder shall have furnished the 

  
 - 4 - 

 
Company, at the Holder’s expense, with (i) an opinion of counsel, reasonably satisfactory to the Company, to the effect that such disposition will not require registration of such
Securities under the Securities Act or (ii) a “no action” letter from the Securities and Exchange Commission to the effect that the transfer of such Securities without registration will not result in a recommendation by the staff of
the Securities and Exchange Commission that action be taken with respect thereto, whereupon such Holder shall be entitled to transfer such Securities in accordance with the terms of the notice delivered by the Holder to the Company. 

(b)    Permitted Transfers. Permitted transfers with respect to Section 5(a) include (and, for the
avoidance of doubt, the Company’s prior written consent and an opinion of counsel is not required for such permitted transfers) (i) a transfer not involving a change in beneficial ownership, or (ii) transactions involving the
distribution without consideration of Securities by any Holder to (x) a parent, subsidiary or other affiliate of a Holder that is a corporation, (y) any of the Holder’s partners, members or other equity owners, or retired partners or
members, or to the estate of any of its partners, members or other equity owners or retired partners or members, or (z) a venture capital fund that is controlled by or under common control with one or more general partners or managing members
of, or shares the same management company with, the Holder; provided, in each case, that the Holder shall give written notice to the Company of the Holder’s intention to effect such disposition and shall have furnished the Company with a
detailed description of the manner and circumstances of the proposed disposition. 
 (c)    Investment
Representation Statement. Unless the rights under this Warrant are exercised pursuant to an effective registration statement under the Securities Act that includes the Shares with respect to which the Warrant was exercised, it shall be a
condition to any exercise of the rights under this Warrant that the Holder shall have confirmed to the satisfaction of the Company in writing, substantially in the form of Exhibit A-1, that the Shares so
purchased are being acquired solely for the Holder’s own account and not as a nominee for any other party, for investment and not with a view toward distribution or resale and that the Holder shall have confirmed such other matter s related
thereto as may be reasonably requested by the Company. 
 (d)    Securities Law Legend. The Securities
shall (unless otherwise permitted by the provisions of this Warrant) be stamped or imprinted with a legend substantially similar to the following (in addition to any legend required by state securities laws): 

THE SECURITIES REPRESENTED HEREBY HAVE NOT BEEN REGISTERED UNDER THE SECURITIES ACT OF 1933, AS AMENDED (THE “ACT”), OR UNDER THE
SECURITIES LAWS OF CERTAIN STATES. THESE SECURITIES MAY NOT BE OFFERED, SOLD OR OTHERWISE TRANSFERRED, PLEDGED OR HYPOTHECATED EXCEPT AS PERMITTED UNDER THE ACT AND APPLICABLE STATE SECURITIES LAWS IN ACCORDANCE WITH APPLICABLE REGISTRATION
REQUIREMENTS OR AN EXEMPTION THEREFROM. THE ISSUER OF THESE SECURITIES MAY REQUIRE AN OPINION OF COUNSEL REASONABLY SATISFACTORY TO THE ISSUE R THAT SUCH OFFER, SALE OR TRANSFER, PLEDGE OR HYPOTHECATION OTHERWISE COMPLIES WITH THE ACT AND ANY
APPLICABLE STATE SECURITIES LAWS. THIS CERTIFICATE MUST BE SURRENDERED TO THE COMPANY OR ITS TRANSFER AGENT AS A CONDITION PRECEDENT TO THE SALE, TRANSFER, PLEDGE OR HYPOTHECATION OF ANY INTEREST IN ANY OF THE SECURITIES REPRESENTED HEREBY. 

(e)    Market Stand-off Legend. The Shares issued upon exercise
hereof shall also be stamped or imprinted with a legend in substantially the following form: 
 THE SHARES REPRESENTED BY THIS CERTIFICATE
ARE SUBJECT TO RESTRICTIONS ON TRANSFERABILITY AND RESALE, INCLUDING A LOCK-UP PERIOD TN THE EVENT OF THE COMPANY’S INITIAL PUBLIC OFFERING, AS SET FORTH IN THE WARRANT PURSUANT TO WHICH THESE SHARES WERE
ISSUED, A COPY OF WHICH MAY BE OBTAINED AT THE PRINCIPAL OFFICE OF THE COMPANY. 
 (f)    Instructions Regarding
Transfer Restrictions. The Holder consents to the Company making a notation on its records and giving instructions to any transfer agent in order to implement the restrictions on transfer established in this Section 5. 

  
 - 5 - 

 (g)    Removal of Legend. The legend referring to federal
and state securities laws identified in Section 5(d) stamped on a certificate evidencing the Shares and the stock transfer instructions and record notations with respect to such securities shall be removed and the Company shall issue a
certificate without such legend to the holder of such securities if (i) such securities are registered under the Securities Act, or (ii) such holder provides the Company with an opinion of counsel reasonably acceptable to the Company to
the effect that a sale or transfer of such securities may be made without registration or qualification. 

(h)    No Transfers to Bad Actors; Notice of Bad Actor Status. To the extent Holder is a beneficial owner of
20% or more of the Company’s outstanding voting equity securities, calculated on the basis of voting power, Holder agrees not to sell, assign, transfer, pledge or otherwise dispose of any securities of the Company, or any beneficial interest
therein, to any person (other than the Company) unless and until the proposed transferee confirms to the reasonable satisfaction of the Company that neither the proposed transferee nor any of its directors, executive officers, other officers that
may serve as a director or officer of any company in which it invests, general partners or managing members nor any person that would be deemed a beneficial owner of those securities (in accordance with Rule 506(d) of the Securities Act) is subject
to any of the “bad actor” disqualifications described in Rule 506(d)(l)(i) through (viii) under the Securities Act, except as set forth in Rule 506(d)(2) or (d)(3) under the Securities Act and disclosed, reasonably in advance of the
transfer, in writing in reasonable detail to the Company. To the extent Investor is a beneficial owner of 20% or more of the Company’s outstanding voting equity securities, calculated on the basis of voting power, Holder will promptly notify
the Company in writing if the Holder or, to the Holder’s knowledge, any person specified in Rule 506(d)(1) under the Securities Act becomes subject to any of the “bad actor” disqualifications described in Rule 506(d)(l)(i) through
(viii) under the Securities Act. 
 6.    Adjustments. Subject to the expiration of this Warrant pursuant to
Section 7, the number and kind of shares purchasable hereunder and the Exercise Price therefor are subject to adjustment from time to time, as follows: 

(a)    Merger or Reorganization. If at any time there shall be any reorganization, recapitalization, merger
or consolidation (a “Reorganization”) involving the Company (other than as otherwise provided for herein or as would cause the expiration of this Warrant under Section 7) in
which shares of the Company’s stock are converted into or exchanged for securities, cash or other property, then, as a part of such Reorganization, lawful provision shall be made so that the Holder shall thereafter be entitled to receive upon
exercise of this Warrant, the kind and amount of securities, cash or other property of the successor corporation resulting from such Reorganization, equivalent in value to that which a holder of the Shares deliverable upon exercise of this Warrant
would have been entitled in such Reorganization if the right to purchase the Shares hereunder had been exercised immediately prior to such Reorganization. In any such case, appropriate adjustment (as determined in good faith by the Board of
Directors of the successor corporation) shall be made in the application of the provisions of this Warrant with respect to the rights and interests of the Holder after such Reorganization to the end that the provisions of this Warrant shall be
applicable after the event, as near as reasonably may be, in relation to any shares or other securities deliverable after that event upon the exercise of this Warrant. 

(b)    Reclassification of Shares. If the securities issuable upon exercise of this Warrant are changed into
the same or a different number of securities of any other class or classes by reclassification, capital reorganization or otherwise (other than as otherwise provided for herein) (a
“Reclassification”), then, in any such event, in lieu of the number of Shares which the Holder would otherwise have been entitled to receive, the Holder shall have the right
thereafter to exercise this Warrant for a number of shares of such other class or classes of stock that a holder of the number of securities deliverable upon exercise of this Warrant immediately before that change would have been entitled to receive
in such Reclassification, all subject to further adjustment as provided herein with respect to such other shares. 

(c)    Subdivisions and Combinations. In the event that the outstanding shares of common stock are
subdivided (by stock split , by payment of a stock dividend or otherwise) into a greater number of shares of such securities, the number of Shares issuable upon exercise of the rights under this Warrant immediately prior to such subdivision shall,
concurrently with the effectiveness of such subdivision, be proportionately increased, and the Exercise Price shall be proportionately decreased , and in the event that the outstanding shares of common stock are combined (by reclassification or
otherwise) into a lesser number of shares of such securities, the number of Shares issuable upon exercise of the rights under this Warrant immediately prior to such combination shall, concurrently 

  
 - 6 - 

 
with the effectiveness of such combination, be proportionately decreased, and the Exercise Price shall be proportionately increased. 

(d)    Notice of Adjustments. Upon any adjustment in accordance with this Section 6, the Company shall
give notice thereof to the Holder, which notice shall state the event giving rise to the adjustment, the Exercise Price as adjusted and the number of securities or other property purchasable upon the exercise of the rights under this Warrant,
setting forth in reasonable detail the method of calculation of each. The Company shall, upon the written request of any Holder, furnish or cause to be furnished to such Holder a certificate setting forth (i) such adjustments, (ii) the
Exercise Price at the time in effect and (iii) the number of securities and the amount, if any, of other property that at the time would be received upon exercise of this Warrant. 

7.    Expiration of the Warrant. This Warrant shall expire and shall no longer be exercisable as of the earlier of:

 (a)    5:00 p.m., Pacific time, on the ten year anniversary of the issuance date of this Warrant, or, if such day is
a not a Business Day, on the next Business Day; or 
 (b)    (i) the acquisition of the Company by another entity by
means of any transaction or series of related transactions to which the Company is a party (including, without limitation, any stock acquisition, reorganization, merger or consolidation, but excluding any sale of stock for capital raising purposes
and any transaction effected primarily for purposes of changing the Company’s jurisdiction of incorporation) other than a transaction or series of related transactions in which the holders of the voting securities of the Company outstanding
immediately prior to such transaction or series of related transactions retain, immediately after such transaction or series of transactions, as a result of shares in the Company held by such holders prior to such transaction or series of
transactions, at least a majority of the total voting power represented by the outstanding voting securities of the Company or such other surviving or resulting entity (or if the Company or such other surviving or resulting entity is a wholly-owned
subsidiary immediately following such acquisition, its parent), or (ii) a sale, lease or other disposition of all or substantially all of the assets of the Company and its subsidiaries taken as a whole by means of any transaction or series of
related transactions, except where such sale, lease or other disposition is to a wholly-owned subsidiary of the Company 
 The Company shall
send to the Holder of this Warrant at least ten (10) days prior written notice of the date of any such event specified in clause (a) or (b), as applicable. The notice provisions set forth in this section may be shortened or waived
prospectively or retrospectively by the consent of the Requisite Holders (as defined in the Notes). 
 As used herein, “Business
Day” shall mean any day, except a Saturday, Sunday or legal holiday, on which bank institutions in the city of Palo Alto, CA are authorized or obligated by law or executive order to close. 

8.    No Rights as a Stockholder. Nothing contained herein shall entitle the Holder to any rights as a stockholder
of the Company or to be deemed the holder of any securities that may at any time be issuable on the exercise of the rights hereunder for any purpose nor shall anything contained herein be construed to confer upon the Holder , as such, any right to
vote for the election of directors or upon any matter submitted to stockholders at any meeting thereof, or to give or withhold consent to any corporate action (whether upon any recapitalization, issuance of stock, reclassification of stock, change
of par value or change of stock to no par value, consolidation, merger, conveyance or otherwise) or to receive notice of meetings, or to receive dividends or subscription rights or any other rights of a stockholder of the Company until the rights
under the Warrant shall have been exercised and the Shares purchasable upon exercise of the rights hereunder shall have become deliverable as provided herein. 

9.    Market Stand-off. The Holder of this Warrant hereby agrees that such
Holder shall not sell or otherwise transfer, make any short sale of, grant any option for the purchase of, or enter into any hedging or similar transaction with the same economic effect as a sale, of any common stock (or other securities) of the
Company held by the Holder (other than those included in the registration) immediately prior to the Company’s initial public offering during the one hundred eighty (180) day period following the effective date of the registration statement
for the Company’s initial public offering filed under the Securities Act (or such other period as may be requested by the 

  
 - 7 - 

 
Company or an underwriter to accommodate regulatory restrictions on (i) the publication or other distribution of research reports and (ii) analyst recommendations and opinions,
including , but not limited to, the restrictions contained in FINRA Rule 2711(f)(4) or NYSE Rule 472(f)(4), or any successor provisions or amendments thereto). The obligations described in this section shall not apply to a registration relating
solely to employee benefit plans on Form S-1 or Form S-8 or similar forms that may be promulgated in the future, or a registration relating solely to a transaction on
Form S-4 or similar forms that may be promulgated in the future. This Section 9 shall apply only to the Company’s initial public offering , shall not apply to the sale of any shares to an underwriter
pursuant to an underwriting agreement and shall only be applicable to the Holder if all officers, directors and greater than one percent (l%) stockholders of the Company enter into similar agreements. The Company may impose stop-transfer
instructions and may stamp each certificate with a legend as substantially set forth in Section 5(e) with respect to the shares of common stock (or other securities) subject to the foregoing restriction until the end of such one hundred eighty
(180) day (or other) period. The Holder agrees to execute a market stand-off agreement with the underwriters in the offering in customary form consistent with the provisions of this section. 

10.    Representations and Warranties of the Holder. By acceptance of this Warrant, the Holder represents and
warrants to the Company as follows: 
 (a)    No Registration. The Holder understands that the Securities
have not been, and will not be, registered under the Securities Act by reason of a specific exemption from the registration provisions of the Securities Act, the availability of which depends upon, among other things, the bona fide nature of
the investment intent and the accuracy of the Holder’s representations as expressed herein or otherwise made pursuant hereto. 

(b)    Investment Intent. The Holder is acquiring the Securities for investment for its own account, not as
a nominee or agent, and not with a view to, or for resale in connection with, any distribution thereof. The Holder has no present intention of selling, granting any participation in, or otherwise distributing the Securities, nor does it have any
contract, undertaking, agreement or arrangement for the same. 
 (c)    Investment Experience. The Holder
has substantial experience in evaluating and investing in private placement transactions of securities in companies similar to the Company, and has such knowledge and experience in financial or business matters so that it is capable of evaluating
the merits and risks of its investment in the Company and protecting its own interests. 
 (d)    Speculative
Nature of Investment. The Holder understands and acknowledges that the Company has a limited financial and operating history and that its investment in the Company is highly speculative and involves substantial risks. The Holder can bear the
economic risk of its investment and is able, without impairing its financial condition, to hold the Securities for an indefinite period of time and to suffer a complete loss of its investment. 

(e)    Access to Data. The Holder has had an opportunity to ask questions of officers of the Company, which
questions were answered to its satisfaction. The Holder believes that it has received all the information that it considers necessary or appropriate for deciding whether to acquire the Securities. The Holder understands that any such discussions, as
well as any information issued by the Company, were intended to describe certain aspects of the Company’s business and prospects, but were not necessarily a thorough or exhaustive description. The Holder acknowledges that any business plans
prepared by the Company have been, and continue to be, subject to change and that any projections included in such business plans or otherwise are necessarily speculative in nature, and it can be expected that some or all of the assumptions
underlying the projections will not materialize or will vary significantly from actual results. The foregoing does not, however, limit or modify the representations and warranties of the Company in Section 2 of the Purchase Agreement or the
right of the Holder to rely thereon. 
 (f)    Accredited Investor. The Holder is an “accredited
investor” within the meaning of Regulation D, Rule 501(a), promulgated by the Securities and Exchange Commission and agrees to submit to the Company such further assurances of such status as may be reasonably requested by the Company. The
Holder has furnished or made available any and all information requested by the Company or otherwise necessary to satisfy any applicable verification requirements as to “accredited investor” status. Any such information is true, correct,
timely and complete. 

  
 - 8 - 

 (g)    Residency. The residency of the Holder (or, in the
case of a partnership or corporation, such entity’s principal place of business) is correctly set forth on the signature page hereto. 

(h)    Restrictions on Resales. The Holder acknowledges that the Securities must be held indefinitely unless
subsequently registered under the Securities Act or an exemption from such registration is available. The Holder is aware of the provisions of Rule 144 promulgated under the Securities Act, which permit resale of shares purchased in a private
placement subject to the satisfaction of certain conditions, which may include, among other things, the avail ability of certain current public information about the Company; the resale occurring not less than a specified period after a party has
purchased and paid for the security to be sold; the number of shares being sold during any three-month period not exceeding specified limitations; the sale being effected through a “broker’s transaction,” a transaction directly with a
“market maker” or a “riskless principal transaction” (as those terms are defined in the Securities Act or the Securities Exchange Act of 1934, as amended, and the rules and regulations promulgated thereunder); and the filing of a
Form 144 notice, if applicable. The Holder acknowledges and understands that the Company may not be satisfying the current public information requirement of Rule 144 at the time the Holder wishes to sell the Securities and that, in such event, the
Holder may be precluded from selling the Securities under Rule 144 even if the other applicable requirements of Rule 144 have been satisfied. The Holder acknowledges that, in the event the applicable requirements of Rule 144 are not met,
registration under the Securities Act or an exemption from registration will be required for any disposition of the Securities. The Holder understands that, although Rule 144 is not exclusive, the Securities and Exchange Commission has expressed its
opinion that persons proposing to sell restricted securities received in a private offering other than in a registered offering or pursuant to Rule 144 will have a substantial burden of proof in establishing that an exemption from registration is
available for such offers or sales and that such persons and the brokers who participate in the transactions do so at their own risk. 

(i)    No Public Market. The Holder understands and acknowledges that no public market now exists for any of
the securities issued by the Company and that the Company has made no assurances that a public market will ever exist for the Company’s securities. 

(j)    Brokers and Finders. The Holder has not engaged any brokers, finders or agents in connection with the
Securities, and the Company has not incurred nor will incur, directly or indirectly, as a result of any action taken by the Holder, any liability for brokerage or finders ‘fees or agents’ commissions or any similar charges in connection
with the Securities. 
 (k)    Legal Counsel. The Holder has had the opportunity to review this Warrant,
the exhibits and schedules attached hereto and the transactions contemplated by this Warrant with its own legal counsel. The Holder is not relying on any statements or representations of the Company or its agents for legal advice with respect to
this investment or the transactions contemplated by this Warrant. 
 (l)    Tax Advisors. The Holder has
reviewed with its own tax advisors the U.S. federal, state and local and non-U.S. tax consequences of this investment and the transactions contemplated by this Warrant. With respect to such matters, the Holder
relies solely on any such advisors and not on any statements or representations of the Company or any of its agents, written or oral. The Holder understands that it (and not the Company) shall be responsible for its own tax liability that may arise
as a result of this investment and the transactions contemplated by this Warrant. 
 (m)    No
“Bad Actor” Disqualification. To the extent Holder is a beneficial owner of 20% or more of the Company’s outstanding voting equity securities, calculated on the basis of
voting power, neither (i) the Holder, (ii) any of its directors, executive officers, other officers that may serve as a director or officer of any company in which it invests, general partners or managing members , nor (iii) any
beneficial owner of any of the Company’s voting equity securities (in accordance with Rule 506(d) of the Securities Act) held by the Holder is subject to any of the “ bad actor” disqualifications described in Rule 506(d)(I)(i) through
(viii) under the Securities Act, except as set forth in Rule 506(d)(2) or (d)(3) under the Securities Act and disclosed, reasonably in advance of the acceptance of this Warrant, in writing in reasonable detail to the Company. 

  
 - 9 - 

 11.    Miscellaneous. 

(a)    Amendments. Except as expressly provided herein, neither this Warrant nor any term hereof may be
amended, waived, discharged or terminated other than by a written instrument referencing this Warrant and signed by the Company and the Requisite Holders; provided, that, any such amendment, waiver, discharge or termination shall apply equally to
all of the Warrants issued under the Purchase Agreement (unless consented to by such disparately treated Holder). Any amendment, waiver, discharge or termination of the Warrants (or any term thereof) in accordance with the immediately preceding
sentence shall apply equally to any shares of Common Stock previously issued upon exercise of any of the Warrants issued under the Purchase Agreement. 

(b)    Waivers. No waiver of any single breach or default shall be deemed a waiver of any other breach or
default theretofore or thereafter occurring. 
 (c)    Notices. All notices and other communications
required or permitted hereunder shall be in writing and shall be mailed by registered or certified mail, postage prepaid, sent by facsimile or electronic mail (if to the Holder) or otherwise delivered by hand, messenger or courier service addressed:

 (i)    if to the Holder, to the Holder at the Holder’s address, facsimile number or electronic mail address as
shown in the Company’s records, as may be updated in accordance with the provisions hereof, or until any such Holder so furnishes an address, facsimile number or electronic mail address to the Company, then to and at the address, facsimile
number or electronic mail address of the last holder of this Warrant for which the Company has contact information in its records; or 

(ii)    if to the Company, to the attention of the President or Chief Financial Officer of the Company at the
Company’s address as the Company shall have furnished to the Holder, with a copy (which shall not constitute notice) to [                    ],
Wilson Sonsini Goodrich & Rosati, P.C., 650 Page Mill Road, Palo Alto, CA 94304. 
 Each such notice or other communication shall
for all purposes of this Warrant be treated as effective or having been given (i) if delivered by hand, messenger or courier service, when delivered (or if sent via a nationally-recognized overnight courier service, freight prepaid, specifying next-business-day deli very, one business day after deposit with the courier), or (ii) if sent via mail, at the earlier of its receipt or five days after the same has been deposited in a regularly-maintained
receptacle for the deposit of the United States mail, addressed and mailed as aforesaid, or (iii) if sent via facsimile, upon confirmation of facsimile transfer or, if sent via electronic mail, upon confirmation of delivery when directed to the
relevant electronic mail address, if sent during normal business hours of the recipient, or if not sent during normal business hours of the recipient, then on the recipient’s next business day. In the event of any conflict between the
Company’s books and records and this Warrant or any notice delivered hereunder, the Company’s books and records will control absent fraud or error. 

(d)    Governing Law. This Warrant and all actions arising out of or in connection with this Warrant shall
be governed by and construed in accordance with the laws of the State of Delaware, without regard to the conflicts of law provisions of the State of Delaware, or of any other state. 

(e)    Jurisdiction and Venue. Each of the Holder and the Company irrevocably consents to the exclusive
jurisdiction and venue of any court within Delaware, in connection with any matter based upon or arising out of this Warrant or the matters contemplated herein, and agrees that process may be served upon them in any manner authorized by the laws of
the State of Delaware for such persons. 
 (f)    Titles and Subtitles. The titles and subtitles used in
this Warrant are used for convenience only and are not to be considered in construing or interpreting this Warrant. All references in this Warrant to sections, paragraphs and exhibits shall, unless otherwise provided, refer to sections and
paragraphs hereof and exhibits attached hereto. 
 (g)    Severability. If any provision of this Warrant
becomes or is declared by a court of competent jurisdiction to be illegal, unenforceable or void, portions of such provision, or such provision in its 

  
 - 10 - 

 
entirety, to the extent necessary, shall be severed from this Warrant, and such illegal, unenforceable or void provision shall be replaced with a valid and enforceable provision that will
achieve, to the extent possible, the same economic, business and other purposes of the illegal, unenforceable or void provision. The balance of this Warrant shall be enforceable in accordance with its terms. 

(h)    Waiver of Jury Trial. EACH OF THE HOLDER AND THE COMPANY WAIVES, TO THE FULLEST EXTENT PERMITTED
BY LAW, ANY AND ALL RIGHT TO TRIAL BY JURY IN ANY LEGAL PROCEEDING (WHETHER BASED ON CONTRACT, TORT OR OTHERWISE) ARISING OUT OF OR RELATED TO THIS WARRANT. 

(i)    California Corporate Securities Law. THE SALE OF THE SECURITIES THAT ARE THE SUBJECT OF THIS WARRANT
HAS NOT BEEN QUALIFIED WITH THE COMMISSIONER OF CORPORATIONS OF THE STATE OF CALIFORNIA AND THE ISSUANCE OF SUCH SECURITIES OR THE PAYMENT OR RECEIPT OF ANY PART OF THE CONSIDERATION THEREFOR PRIOR TO SUCH QUALIFICATION IS UNLAWFUL, UNLESS THE SALE
OF SECURITIES IS EXEMPT FROM QUALIFICATION BY SECTION 25100, 25102, OR 25105 OF THE CALIFORNIA CORPORATIONS CODE. THE RIGHTS OF ALL PARTIES TO THIS WARRANT ARE EXPRESSLY CONDITIONED UPON THE QUALIFICATION BEING OBTAINED, UNLESS THE SALE IS SO
EXEMPT. 
 (j)    Rights and Obligations Survive Exercise of the Warrant. Except as otherwise provided
herein, the rights and obligations of the Company and the Holder under this Warrant shall survive exercise of this Warrant. 

(k)    Entire Agreement. Except as expressly set forth herein, this Warrant (including the exhibits attached
hereto) constitutes the entire agreement and understanding of the Company and the Holder with respect to the subject matter hereof and supersede all prior agreements and understandings relating to the subject matter hereof. 

(signature page follows) 

  
 - 11 - 

 The Company signs this Warrant as of the date stated on the first page. 

 

			
	ACTUS MEDICAL, INC.
		
	By:	 	  

	Name:	 	  

	Title:	 	  

 (Signature Page to Warrant to Purchase Shares Common Stock of Acutus Medical, Inc.) 

 EXHIBIT A 

 EXHIBIT A-1 

  
 2 

 EXHIBIT B 

  
 3

Source: [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00311-of-00352.parquet"}, [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00311-of-00352.parquet"}]]